Spots Global Cancer Trial Database for carcinoma, neuroendocrine
Every month we try and update this database with for carcinoma, neuroendocrine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | NCT02205515 | Carcinoma, Neur... | Everolimus | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Personalized PRRT of Neuroendocrine Tumors | NCT02754297 | Neuroendocrine ... Carcinoid Tumor Carcinoma, Neur... | 177Lu-Octreotat... | 18 Years - | CHU de Quebec-Universite Laval | |
| Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract | NCT00353015 | Gastrointestina... Carcinoma, Neur... | Cisplatin Irinotecan | - | M.D. Anderson Cancer Center | |
| Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | NCT04488263 | Neuroendocrine ... Carcinoma, Neur... | 3 Years - | National Institutes of Health Clinical Center (CC) | ||
| Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | NCT05237934 | Neuroendocrine ... Carcinoma, Neur... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours | NCT01876771 | Carcinoma, Neur... | [177]Lu-DOTA-TA... | 14 Years - 90 Years | AHS Cancer Control Alberta | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | NCT06406465 | Carcinoma, Neur... Tumor, Neuroend... Tumors, Neuroen... Neuroendocrine;... Small Cell; Rec... | Belinostat Cisplatin Etoposide | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| TheraSphere for the Treatment of Liver Metastases | NCT00511862 | Colorectal Canc... Carcinoma, Neur... Neoplasm Metast... | Yttrium 90 glas... | 18 Years - | Boston Scientific Corporation | |
| TheraSphere for the Treatment of Liver Metastases | NCT00511862 | Colorectal Canc... Carcinoma, Neur... Neoplasm Metast... | Yttrium 90 glas... | 18 Years - | Boston Scientific Corporation | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract | NCT00353015 | Gastrointestina... Carcinoma, Neur... | Cisplatin Irinotecan | - | M.D. Anderson Cancer Center | |
| Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors | NCT01177007 | Liver Neoplasms | TheraSphere, Yt... | 18 Years - | Yale University | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | NCT05237934 | Neuroendocrine ... Carcinoma, Neur... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | NCT04985357 | Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin... | 18 Years - | Travera Inc | ||
| Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | NCT04488263 | Neuroendocrine ... Carcinoma, Neur... | 3 Years - | National Institutes of Health Clinical Center (CC) | ||
| KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | NCT02250885 | Carcinoma, Neur... | Selinexor | 18 Years - | Gabrail Cancer Center Research | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | NCT05461430 | Pleural Effusio... Ascites, Malign... Carcinoma Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Rena... Carcinoma, Smal... Carcinoma, Non-... Carcinoma, Panc... Carcinoma, Neur... Carcinoma, Thym... Carcinoma, Panc... Carcinoma Breas... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Es... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Cholangiocarcin... Melanoma Mesothelioma Pancreatic Canc... | 18 Years - | Travera Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
